The advent and rising prominence of glucagon-like peptide-1 (GLP-1) receptor agonists in the obesity treatment landscape present novel therapeutic avenues for hypothalamic obesity management. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.